PATENT CLAIM ANALYSIS

Application Number: 16191319
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-03
Patent Classification: ["514", "309000"]

Abstract:
The present disclosure relates generally to compositions and methods of treating neoplastic diseases or cancers, such as glioblastoma and non-Hodgkin's lymphomas, or other cancers in which the subject suffers from an advanced solid tumor, comprising a combination of, or administering a combination of, a bromodomain and extra-terminal protein (BET) inhibitor and at least one chemotherapeutic agent, which does not inhibit BET directly. The BET inhibitor/chemotherapeutic agent combination, or combination therapy, can yield synergistic effects, thereby increasing the effectiveness of the cancer treatment as compared with the administration of either the BET inhibitor or the chemotherapeutic agent alone.

Claim (Index 8):
The method of  claim 5 , wherein the chemotherapeutic agent is selected from the group consisting of temozolomide, romidepsin, and protein-bound paclitaxel.

Metadata:
- Claim Count in Document: 7.0
- Percentile: 98.0
- Lexical Diversity: 1.58571
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15796571', '15673084', '11724992', '13321213', '13357477']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8240488528896442
- 35 USC 102 Novelty (BERT): 0.573286104251957
- Combined Prediction Score: 0.7989725780258755
- Mean Citation Score: 356.599036
- Max Citation Score: 558.2782599999998
- Similarity Product: 352.24964678257936

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test